Stay updated with breaking news from Development For Sanofi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The investment will advance the development of a subcutaneous Sarclisa formulation for multiple myeloma (MM) treatment.
Sanofi announces €300 million collaboration with Blackstone Life Sciences to advance an innovative treatment for multiple myeloma Investment will accelerate the overall Sarclisa®... | March 15, 2022
Sanofi and Blackstone (NYSE: BX) today announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences (BXLS)...
Sanofi and Blackstone (NYSE: BX) today announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences (BXLS) will contribute up to €300 million to accelerate the global pivotal studies and the clinical development program for the subcutaneous formulation and delivery of the ...
Sanofi announces €300 million collaboration with Blackstone Life Sciences to advance an innovative treatment for multiple myelomaInvestment will accelerate the overall Sarclisa® development programSanofi will continue to fully manage the clinical program and retain full rights and control of Sarclisa&...